Studying blood samples to predict myeloma progression in screened people
Collects blood samples from people screened for early myeloma and from the general population.
Key facts
- Who runs it
- Tel-Aviv Sourasky Medical Center
- Where
- Beersheba, Haifa, Petah Tikva, and Tel Aviv, IsraelSee the 4 sites
- Trial code
- Registry title
- Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population
- Status
- Recruiting
- People taking part
- 2,000 people, planned
- Started
- 5 Sept 2023
- Expected to end
- Jun 2029
- Type of study
- Observational, 2 groups
- Treatments tested
- blood sampling
- Record updated
- 11 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a family history of a plasma cell disorder or another blood cancer, who have not been diagnosed with one themselves.
- Age
- 30 years or older if you have a first-degree relative with a plasma cell disorder or another blood cancer. 18 years or older if you have 2 or more first- or second-degree relatives with one.
- Sex
- All sexes can join.
Main reasons for not taking part
- Cancer at any site (including blood cancers) with symptoms that needs active treatment
- Already diagnosed with a plasma cell disorder such as MGUS, SMM, MM or Waldenström's Macroglobulinemia
- Positive pregnancy test during screening
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Must meet criteria of the high-risk population as described with one of the below criteria; ≥ 30 years AND; first-degree relative of a patient with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer; OR
- Age ≥ 18 years with 2 or more first- or second-degree relatives with a plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia, or another blood cancer '
- Voluntary written informed consent must be given with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
Who cannot take part
- • Persons diagnosed with cancer at any site (including hematologic cancers) with symptomatic disease requiring active therapy; Persons with an already diagnosed plasma cell dyscrasia such as MGUS, SMM, MM, and Waldenström's Macroglobulinemia; Female patient who have a positive serum pregnancy test during the screening period or a positive pregnancy test
Where in Israel
- SorokaBeersheba, IsraelContact: Miri Zektser, DrTaking people
- Rambam Healthcare CampusHaifa, IsraelContact: Noa Lavi, DrTaking people
- Rabin Medical CenterPetah Tikva, IsraelContact: Juliana Waxman, DrTaking people
- TASMCTel Aviv, IsraelContact: Irit Avivi, MDTaking people
About the trial
What the trial wants to find out
We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions.
Read full original descriptionShow less
Our overarching hypothesis is that early detection of MGUS/SMM in a high- risk population, along with the comprehensive characterization of genomic/epigenomic and microenvironmental/immune regulators of disease progression will lead to strategies that intercept disease progression and improve survival.
The 2 groups in the trial
- First-degree relative of a patient with a plasma cell dyscrasia or another blood cancer.
Individuals will ensure they are eligible by filling out an eligibility questionnaire confirming they meet all eligibility criteria. Individuals will provide informed consent to complete the baseline questionnaire and provide a blood sample that will be used to determine whether they have a monoclonal protein
Treatment: blood sampling
- Control group
The individuals without a relative of a patient with a plasma cell dyscrasia or another blood cancer. This group will undergo the same procedures as the first-degree participants and these data will be used for comparison between the populations.
Treatment: blood sampling
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population
- Plain-language title
- Studying blood samples to predict myeloma progression in screened peopleGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 11 August 2026